Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Top Page
Atossa Therapeutics
(NASDAQ:ATOS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$5.50
▲(16.53% Upside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by very weak financial performance (no revenue, increasing losses, and ongoing cash burn), with only the low-debt profile providing partial support. Technicals remain below key longer-term moving averages, and valuation is challenged by ongoing losses. Positive corporate developments (Nasdaq compliance and pipeline/regulatory progress) provide a meaningful but not decisive offset.
Positive Factors
Low leverage / no debt
The absence of debt materially reduces interest and covenant risk, preserving financial flexibility. For a clinical-stage biotech, low leverage extends runway per dollar of financing and lowers fixed cash obligations, supporting continued R&D investment over the next 2–6 months.
Negative Factors
No commercial revenue
Zero product revenue means the company cannot self-fund operations; it remains fully dependent on external capital. Persistent loss-making status implies continued dilution risk and limited operating resilience if financing markets tighten over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
The absence of debt materially reduces interest and covenant risk, preserving financial flexibility. For a clinical-stage biotech, low leverage extends runway per dollar of financing and lowers fixed cash obligations, supporting continued R&D investment over the next 2–6 months.
Read all positive factors
Atossa Therapeutics (ATOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$40.65M
Dividend YieldN/A
Average Volume (3M)1.16M
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue GrowthN/A
EPS Growth-9.42%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.19
Shares Outstanding8,611,361
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap-0.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit40.82
Enterprise Value/Ebitda0.02
Forecast
1Y Price Target
$18.33Price Target Upside288.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.82
Revenue Forecast (FY)N/A
Atossa Therapeutics Business Overview & Revenue Model
Company Description
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug cand...
How the Company Makes Money
Atossa Therapeutics does not have a broadly established, recurring commercial revenue stream from marketed products; detailed, consistent product-revenue information is null. As a clinical-stage biopharmaceutical company, it typically funds operat...
Atossa Therapeutics Earnings Call Summary
Earnings Call Date:Mar 25, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.Positive Updates
Reduced Operating Expenses
Total operating expenses for the year were $27.6 million, down from $31.4 million in 2023, a decrease of $3.8 million, reflecting disciplined spending in both R&D and G&A.
Negative Updates
Investment Write-off
A write-off of $1.7 million was recorded as Dynamic Cell Therapies ceased operations in the fourth quarter of 2024.
Read all updates
Q4-2024 Updates
Positive
Negative
Reduced Operating Expenses
Total operating expenses for the year were $27.6 million, down from $31.4 million in 2023, a decrease of $3.8 million, reflecting disciplined spending in both R&D and G&A.
Read all positive updates
Company Guidance
In their recent earnings call, Atossa Therapeutics provided guidance highlighting several key metrics. Operating expenses for 2024 decreased to $27.6 million, down from $31.4 million in 2023, due to disciplined spending in R&D and G&A. R&D expenses fell by $3.2 million to $14.1 million, driven by a $2.6 million reduction in spending on (Z)-endoxifen trials. G&A expenses decreased slightly to $13.5 million, with a $1.9 million reduction in compensation costs. The company reported a net loss of $25.5 million or $0.20 per share, compared to $30.1 million or $0.24 per share in the previous year. Atossa closed the year with $71.1 million in cash and cash equivalents, providing a strong financial position to advance their lead program, (Z)-endoxifen, particularly in metastatic breast cancer settings. Additionally, a Phase I study demonstrated a clinical benefit rate of approximately 26% in patients with previous progression on multiple therapies, and a related Phase II study suggested nearly a five-month improvement in progression-free survival for certain subgroups. The company plans to focus on the U.S. FDA process for a streamlined path to market, with further guidance expected as they engage with key opinion leaders and regulatory authorities.Atossa Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -16.00K | -17.00K | -23.00K | -8.00K | -23.00K |
| EBITDA | -37.13M | -27.60M | -31.35M | -27.68M | -20.50M |
| Net Income | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
Balance Sheet | |||||
| Total Assets | 47.61M | 76.44M | 96.25M | 123.53M | 141.26M |
| Cash, Cash Equivalents and Short-Term Investments | 41.30M | 71.08M | 88.46M | 110.89M | 136.38M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M |
| Stockholders Equity | 39.35M | 71.48M | 91.02M | 117.96M | 138.14M |
Cash Flow | |||||
| Free Cash Flow | -29.79M | -21.05M | -20.95M | -20.79M | -16.48M |
| Operating Cash Flow | -29.76M | -21.03M | -20.94M | -20.76M | -16.47M |
| Investing Cash Flow | -23.00K | -19.00K | -14.00K | -4.73M | -9.00K |
| Financing Cash Flow | 0.00 | 3.67M | -1.48M | 0.00 | 113.30M |
Atossa Therapeutics Technical Analysis
Negative
4.72
Price Trends
5.80
Negative
8.46
Negative
10.70
Negative
Market Momentum
-0.12
Negative
41.48
Neutral
18.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATOS, the sentiment is Negative. The current price of 4.72 is below the 20-day moving average (MA) of 4.98, below the 50-day MA of 5.80, and below the 200-day MA of 10.70, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 41.48 is Neutral, neither overbought nor oversold. The STOCH value of 18.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATOS.
Atossa Therapeutics Risk Analysis
Atossa Therapeutics disclosed 48 risk factors in its most recent earnings report. Atossa Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atossa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $303.31M | -6.90 | -23.98% | ― | 946.61% | -11.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $130.17M | 811.87 | -0.04% | ― | -33.41% | 81.19% | |
46 Neutral | $40.65M | -2.19 | -49.42% | ― | ― | -9.42% | |
46 Neutral | $93.66M | -1.64 | -26.04% | ― | 13.77% | -4.76% | |
45 Neutral | $111.24M | -9.60 | -353.36% | ― | -10.36% | 42.36% | |
41 Neutral | $17.67M | -6.72 | 389.21% | ― | ― | -234.46% |
* Healthcare Sector Average
ATOS
Atossa Therapeutics
4.72
-5.72
-54.80%
AGEN
Agenus
3.39
1.79
111.87%
INO
Inovio Pharmaceuticals
1.61
-0.12
-6.94%
OVID
Ovid Therapeutics
2.30
1.95
557.14%
SEER
Seer
1.66
-0.08
-4.60%
TVGN
Tevogen Bio Holdings
4.37
-55.64
-92.73%
Atossa Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Atossa Therapeutics Launches New $50 Million ATM Program
Neutral
Feb 20, 2026
On February 20, 2026, Atossa Therapeutics entered into a new at-the-market offering agreement with Rodman Renshaw LLC, allowing the company to issue and sell up to $50 million of its common stock through the agent on Nasdaq or other trading venue...
Delistings and Listing ChangesRegulatory Filings and Compliance
Atossa Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
Positive
Feb 17, 2026
On February 17, 2026, Atossa Therapeutics, Inc. announced it had regained compliance with Nasdaq’s minimum closing bid price rule, resolving a deficiency first flagged on February 21, 2025, when its stock traded below $1.00 for 30 consecutiv...
Business Operations and StrategyProduct-Related AnnouncementsStock Split
Atossa Therapeutics Issues 2026 Outlook and Strategic Update
Positive
Feb 11, 2026
On February 11, 2026, Atossa Therapeutics issued a shareholder letter reviewing 2025 progress and outlining its 2026 outlook, highlighting advances in its (Z)-endoxifen programs across breast cancer and rare diseases. The company detailed positive...
Shareholder MeetingsStock Split
Atossa Therapeutics Sets 15-for-1 Reverse Stock Split
Neutral
Jan 26, 2026
On December 19, 2025, Atossa Therapeutics stockholders approved an amendment to the company’s Certificate of Incorporation authorizing a reverse stock split of its common stock at a ratio between 5:1 and 20:1, with 33.7 million votes in favo...
Business Operations and StrategyRegulatory Filings and Compliance
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program
Neutral
Jan 9, 2026
In a recent Form 8-K, Atossa Therapeutics furnished a corporate presentation outlining its development and regulatory strategy for its lead program, (Z)-Endoxifen, including potential breast cancer indications and anticipated milestones, while spe...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial
Positive
Jan 6, 2026
On January 6, 2026, Atossa Therapeutics announced that the U.S. Food and Drug Administration issued a “Study May Proceed” letter for the company’s investigational new drug application to study its lead candidate (Z)-Endoxifen in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.